Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
Status:
Active, not recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously
treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma
participants.